Code
Listing of Exposure to Study Drug
——————————————————————————————————————————————————————————————————————————————————————————————————————————————
Study Day Study Day
Treatment Center/Subject ID Visit From To Dose Unit Frequency Route
——————————————————————————————————————————————————————————————————————————————————————————————————————————————
A: Drug X BRA-1/id-105 SCREENING -1 -1 960 mg ONCE INTRAVENOUS
BASELINE 1 1 960 mg ONCE INTRAVENOUS
WEEK 1 DAY 8 8 8 720 mg ONCE SUBCUTANEOUS
WEEK 2 DAY 15 15 15 480 mg ONCE INTRAVENOUS
WEEK 3 DAY 22 22 22 480 mg ONCE INTRAVENOUS
WEEK 4 DAY 29 29 29 720 mg ONCE INTRAVENOUS
WEEK 5 DAY 36 36 36 720 mg ONCE INTRAVENOUS
BRA-1/id-134 SCREENING -1 -1 960 mg ONCE INTRAVENOUS
BASELINE 1 1 720 mg ONCE INTRAVENOUS
WEEK 1 DAY 8 8 8 720 mg ONCE INTRAVENOUS
WEEK 2 DAY 15 15 15 960 mg ONCE INTRAVENOUS
WEEK 3 DAY 22 22 22 720 mg ONCE INTRAVENOUS
WEEK 4 DAY 29 29 29 960 mg ONCE INTRAVENOUS
WEEK 5 DAY 36 36 36 960 mg ONCE INTRAVENOUS
BRA-1/id-42 SCREENING -1 -1 960 mg ONCE INTRAVENOUS
BASELINE 1 1 960 mg ONCE INTRAVENOUS
WEEK 1 DAY 8 8 8 720 mg ONCE SUBCUTANEOUS
WEEK 2 DAY 15 15 15 720 mg ONCE INTRAVENOUS
WEEK 3 DAY 22 22 22 720 mg ONCE INTRAVENOUS
WEEK 4 DAY 29 29 29 480 mg ONCE INTRAVENOUS